WO2009138224A1 - Composition pharmaceutique comprenant du drospirénone - Google Patents

Composition pharmaceutique comprenant du drospirénone Download PDF

Info

Publication number
WO2009138224A1
WO2009138224A1 PCT/EP2009/003409 EP2009003409W WO2009138224A1 WO 2009138224 A1 WO2009138224 A1 WO 2009138224A1 EP 2009003409 W EP2009003409 W EP 2009003409W WO 2009138224 A1 WO2009138224 A1 WO 2009138224A1
Authority
WO
WIPO (PCT)
Prior art keywords
drospirenone
pharmaceutical composition
pharmaceutically acceptable
hpmc
present
Prior art date
Application number
PCT/EP2009/003409
Other languages
English (en)
Inventor
Sonja Lieb
Original Assignee
Helm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helm Ag filed Critical Helm Ag
Publication of WO2009138224A1 publication Critical patent/WO2009138224A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Definitions

  • composition comprising Drospirenone
  • the present invention relates to a pharmaceutical composition comprising drospirenone, to a solid pharmaceutical composition obtainable by direct compression of said pharmaceutical composition and to a process for the preparation of said pharmaceutical composition.
  • Drospirenone having the chemical name 6 ⁇ ,7 ⁇ ,15 ⁇ ,16 ⁇ -Dimethylen-3-oxo-17 ⁇ -pregn-4- en-21 ,17-carbolactone, is represented by the formula below.
  • Drospirenone is a synthetic gestagen that shows additional aldosterone-antagonistic and antiandrogen properties. It is known since 1976 and it is used as an oral contraceptive, e.g. in combination with ethinylestradiol. Drospirenone is hardly soluble in water or aqueous buffer solutions and thus shows a low dissolution rate and bioavailability.
  • Fotherby discloses that the disintegration rate and the dissolution rate, which are important aspects of bioavailability, can be improved by grinding the active component to a very fine state (micronization) to increase the surface area of the drug. This results in an increase in the dissolution rate and hence in absorption (Bioavailability of Orally Administered Sex Steroids Used in Oral Contraception and Hormone Replacement Therapy, Fotherby, Contraception 1996, 54, 59-69).
  • WO 2001/015701 A1 discloses to improve the dissolution profile of drospirenone by dissolving drospirenone in a suitable solvent and spraying this solution onto the surface of inert carrier particles.
  • WO 2005/087194 A1 relates to pharmaceutical compositions comprising steroidal drugs, such as drospirenone, in a molecularly dispersed form.
  • WO 2005/087199 A2 relates to pharmaceutical compositions comprising a powder of lipophilic compounds, such as drospirenone, in molecularly dispersed form together with a carrier having a specific surface area of at least 250 m 2 /g.
  • micronization techniques are costly, difficult to handle and require special equipment.
  • micronization of highly active substances have to be carried out under special precautions to avoid contact of the environment with the highly active substance. These precautions are costly and, therefore, economically disadvantageous.
  • electrostatic charging often results in particles which show disadvantageous flow properties making these particles inapplicable for most formulation techniques, such as direct compression.
  • drospirenone has a low chemical stability. Under acidic conditions, drospirenone is rapidly degraded to a physiologically inactive substance. Under alkaline conditions, drospirenone undergoes hydrolysis. Such degradation reactions in particular occur in wet granulation processes or when drospirenone is dissolved and sprayed onto carrier particles. Moreover, molecularly dispersing drospirenone in carriers may reduce the availability of the drug due to interactions of drospirenone and the carrier matrix. Additionally, such processes are costly due to the required special technical equipment.
  • compositions comprising drospirenone, wherein the drospirenone is chemically and morphologically stable, fast dissolving and showing improved bioavailability.
  • a pharmaceutical composition comprising drospirenone substantially in amorphous form and a certain pharmaceutically acceptable carrier and the drospirenone and the pharmaceutically acceptable carrier are present in a co-milled state.
  • drospirenone exhibits good chemical stability, excellent dissolution properties and bioavailability.
  • co-milling drospirenone and the pharmaceutically acceptable carrier an improved dissolution in aqueous systems is achieved, compared to the dissolution of known crystalline forms of drospirenone.
  • the drospirenone particles can be easily and cost effectively prepared, show excellent flow properties and can thus be further processed in a simple manner, for example by direct compression, to obtain solid pharmaceutical dosage forms.
  • the present invention therefore relates to a pharmaceutical composition
  • a pharmaceutical composition comprising drospirenone, wherein the drospirenone is present in the composition substantially in amorphous form, the composition comprises a pharmaceutically acceptable carrier selected from the group consisting of hydroxypropylmethylcellulose (HPMC), polyvinylpyrrolidone (PVP), and microcrystalline cellulose (MCC), and the drospirenone and the pharmaceutically acceptable carrier are present in a co-milled state.
  • HPMC hydroxypropylmethylcellulose
  • PVP polyvinylpyrrolidone
  • MCC microcrystalline cellulose
  • Drospirenone is known in the art. It can, for example, be prepared according to the methods disclosed in DE 26 52 761 and DE 30 22 337. Drospirenone is present in the pharmaceutical composition of the present invention substantially in amorphous form. Preferably more than about 90 wt%, more preferably more than about 95 wt%, such as more than about 99 wt% / in particular about 100 wt% of drospirenone based on the total weight of the drospirenone is present in amorphous form.
  • amorphous describes a solid devoid of long-range crystalline order. Such amorphous form of a solid can be identified by the lack of discrete peaks in an X-ray powder diffraction pattern and/or the observation of a glass transition point in a DSC diagram.
  • the pharmaceutical composition of the present invention further comprises a pharmaceutically acceptable carrier.
  • the carrier is selected from the group consisting of hydroxypropylmethylcellulose (HPMC), polyvinylpyrrolidone (PVP), such as povidone K12, and povidone K30, and microcrystalline cellulose (MCC). Most preferred is HPMC.
  • Drospirenone and the pharmaceutically acceptable carrier are present in the pharmaceutical composition of the present invention in a co-milled state.
  • co-milled state means that the drospirenone particles and the particles of the pharmaceutically acceptable carrier are mixed and the mixture is milled or both ingredients are milled together to from a mixture.
  • co-milling is conducted without addition of any further ingredients.
  • the co-milling results in a two-phase system of distinct drospirenone and carrier particles wherein the particles are, however, in more intimate contact with each other than in a mere blend of the compounds. The difference between a co-milled product and a blend will be explained in more detail below.
  • the co-milled state of drospirenone and the pharmaceutically acceptable carrier can be obtained by intensively mixing drospirenone and the pharmaceutically acceptable carrier in a suitable milling equipment, for example a ball milling equipment, such as a planetary ball mill (e.g. Pulverisette ® ) or an agitator ball mill.
  • a suitable milling equipment for example a ball milling equipment, such as a planetary ball mill (e.g. Pulverisette ® ) or an agitator ball mill.
  • the pharmaceutical composition according to the present invention can comprise about 5 wt% to about 75 wt% of drospirenone, preferably about 20 wt% to about 75 wt% of drospirenone, in particular about 25 wt% to about 75 wt% of drospirenone, based on the total weight of the composition.
  • the ratio of drospirenone to the pharmaceutically acceptable carrier in the pharmaceutical composition of the present invention is about 3:1 to about 1 :10, more preferably about 1 :1 to about 1 :5, in particular about 1 :2 to about 1 :3, such as about 1 :2.5, based on parts per weight.
  • the pharmaceutical composition of the present invention may further comprise suitable pharmaceutically acceptable excipients and adjuvants, for example selected from the group consisting of fillers, disintegrants, binders, glidants and lubricants.
  • suitable pharmaceutically acceptable excipients and adjuvants for example selected from the group consisting of fillers, disintegrants, binders, glidants and lubricants.
  • coloring and/or sweetening agents can be added.
  • the pharmaceutical composition of the present invention is intended to be subjected to direct compression to obtain a solid pharmaceutical composition, the excipients and adjuvants are selected such that they are suitable for direct compression. Which excipients and adjuvants are suitable for direct compression can be determined by standard methods and is known to a person skilled in the art.
  • fillers celluloses and cellulose derivatives such as microcrystalline cellulose, powder cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose and methylcellulose; sugars, such as lactose, fructose, saccharose, glucose and maltose; sugar alcohols, such as lactitol, mannitol, sorbitol, and xylitol; inorganic fillers, such as calcium phosphates and calcium sulfates; and starches and starch derivatives, such as corn starch, potato starch, wheat starch, dextrins, and pregelatinized starches can be exemplified.
  • sugars such as lactose, fructose, saccharose, glucose and maltose
  • sugar alcohols such as lactitol, mannitol, sorbitol, and xylitol
  • inorganic fillers such as calcium phosphates and calcium sulfates
  • starches and starch derivatives such as corn
  • the pharmaceutical composition of the present invention preferably contains about 0 wt% to about 95 wt% of a filler, more preferably about 1 wt% to about 85 wt% of a filler, most preferably about 20 wt% to about 80 wt% of a filler, based on the total weight of the composition.
  • starches modified starches, sodium starch glycolate, pregelatinized starch, celluloses, such as microcrystalline cellulose, carboxymethyl cellulose, modified sodium carboxymethyl cellulose, e.g. crosscarmellose sodium, crospovidone and mixtures thereof can be exemplified.
  • the pharmaceutical composition of the present invention preferably contains about 0 wt% to about 50 wt% of a disintegrant, more preferably about 1 wt% to about 25 wt% of a disintegrant, in particular about 3 wt% to about 20 wt% of a disintegrant, based on the total weight of the composition.
  • the pharmaceutical composition of the present invention may further comprise one or more suitable binders, for example povidone and its derivatives.
  • Binders are preferably present in an amount of about 0 wt% to about 50 wt%, preferably about 1 wt% to about 25 wt%, in particular about 3 wt% to about 20 wt%, based on the total weight of the composition.
  • the pharmaceutical composition of the present invention may further comprise one or more glidants, such as talc and/or silicon dioxide, e.g. colloidal silicon dioxide.
  • the pharmaceutical composition of the present invention preferably contains about 0 wt% to about 10 wt% of a glidant, more preferably about 0.1 wt% to about 7.5 wt% of a glidant, in particular about 0.1 wt% to about 5 wt% of a glidant, such as about 0.1 wt% to about 3 wt% of a glidant, based on the total weight of the composition.
  • the pharmaceutical composition of the present invention may further comprise one or more lubricants.
  • Suitable lubricants are for example stearic acid and derivatives thereof, such as calcium stearate, sodium stearyl fumarate or magnesium stearate, as well as glycerol stearate and hydrogenated vegetable oil.
  • the lubricant may be present in an amount of about 0 wt% to about 10 wt%, preferably about 0.1 wt% to about 10 wt%, in particular about 0.1 wt% to about 7.5 wt%, such as about 0.1 wt% to about 3 wt%, based on the total weight of the composition.
  • the pharmaceutical composition of the present invention contains about 0 wt% to about 95 wt%, preferably about 1 wt% to about 85 wt%, in particular about 20 wt% to about 80 wt% of a filler, about 0 wt% to about 50 wt%, more preferably about 1 wt% to about 25 wt%, in particular about 3 wt% to about 20 wt% of a disintegrant, about 0 wt% to about 50 wt%, more preferably about 1 wt% to about 25 wt%, in particular about 3 wt% to about 20 wt% of a binder, about 0 wt% to about 10 wt%, more preferably about 0.1 wt% to about 5 wt%, in particular about 0.1 wt% to about 3 wt% of a glidant, and about 0 wt% to about 10 wt%, more preferably about 0.1 wt% to about 95
  • the amounts of the ingredients of the pharmaceutical composition have to sum up to 100 wt%.
  • the present invention further relates to a solid dosage form, preferably a tablet, in particular an immediate release tablet, which is most preferably obtainable by direct compression.
  • the ratio of the pharmaceutically acceptable excipients and adjuvants to the co-milled composition comprising drospirenone and the pharmaceutically acceptable carrier is in the range from about 1 :10 to about 30:1 , more preferably in the range from about 1 :5 to about 10:1 , based on parts per weight.
  • the present invention further relates to a process for the preparation of a pharmaceutical composition as described above, i.e. comprising drospirenone which is substantially in amorphous form and a pharmaceutically acceptable carrier selected from the group consisting of hydroxypropylmethylcellulose (HPMC), polyvinylpyrrolidone (PVP), and microcrystalline cellulose (MCC), drospirenone and the pharmaceutically acceptable carrier being present in a co-milled state, the process comprising the step of
  • the co-milling step of the process of the present invention (step a)) can be carried out as described above to obtain an intimate mixture of drospirenone and the pharmaceutically acceptable carrier in a co-milled state, preferably without using any solvent, thus, it is preferred to provide a mixture of drospirenone and a pharmaceutically acceptable carrier and to intensively blend said mixture in a suitable milling equipment, such as a ball mill or agitator bail mill.
  • a suitable milling equipment such as a ball mill or agitator bail mill.
  • the process further comprises the step of adding one or more pharmaceutically acceptable excipients or adjuvants (step b)), whereby the preferred excipients and adjuvants and the preferred amounts to be used are such as described above.
  • the mixture obtained in above steps a) or b) is used for the preparation of a solid dosage form, preferably a tablet, in particular an immediate release tablet.
  • a solid dosage form preferably a tablet, in particular an immediate release tablet.
  • the mixture obtained in step a) or step b) is subjected to direct compression.
  • Devices and conditions how to conduct compression, in particular direct compression, of a pharmaceutical composition are known to a person skilled in the art.
  • the solid pharmaceutical composition of the present invention which is in particular a tablet, contains about 2 mg to about 4 mg of drospirenone per single dosage unit.
  • the pharmaceutical composition comprises as additional pharmaceutically active ingredient ethinylestradiol.
  • the pharmaceutical composition contains the additional pharmaceutically active ingredient in an amount of about 0.01 mg to about 0.05 mg per single dosage unit.
  • the solid dosage form of the present invention is coated.
  • Suitable coatings or films are for example prepared from polymethacrylates, such as Eudragit ® , methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, cellulose acetate phthalate and/or shellac.
  • drospirenone exhibits a good chemical stability although it is in amorphous form.
  • the chemical stability of a composition comprising drospirenone (DRSP) being co-milled with HPMC in a ratio of 1 :2 is demonstrated by storage of said composition at 25°C and 75 % relative humidity over 3 months. The results are summerized in the following table:
  • the pharmaceutical composition shows improved and advantageous dissolution of drospirenone in aqueous systems as compared to known compositions comprising drospirenone in crystalline form.
  • the pharmaceutical composition of the present invention releases drospirenone completely.
  • the Raman spectra at these positions are shown in Figures 9 and 10. From these spectra, it can be determined which material is mainly present at the specific position of the sample. Thus, the ratio of the concentration of drospirenone to HPMC can be determined for each position of the Raman image. Regarding the Raman image shown in Figure 8, it can be seen that there are small areas showing a high drospirenone signal, e.g. at the "cross" area, and areas showing a rather low drospirenone signal and an increase in the HPMC signal, e.g. the "circle” area. In general, the areas with high drospirenone / low HPMC and low drospirenone / high HPMC signals do not exceed roughly 10 by 10 ⁇ m each.
  • Figure 16 shows the Raman image of micronized drospirenone which was blended with HPMC. In this image, much larger areas are observed, wherein the drospirenone signal is constantly high (Figure 17) or the HPMC signal is constantly high (Figure 18), respectively.
  • Figure 19 shows a Raman image of molecularly dispersed drospirenone in HPMC. Due to the homogenous distribution of drospirenone in the HPMC, the Raman image does not show significant differences at different positions, i.e. the spectra at two positions of this map are rather similar ( Figures 20 and 21).
  • Figure 22 shows a Raman map of drospirenone sprayed onto HPMC.
  • the co-milled drospirenone/HPMC i.e. the preferred pharmaceutical composition according to the present invention
  • the comparative measurements demonstrate that such a distribution is not obtained by processes as described in the prior art, i.e. blending of micronized drospirenone with a carrier, molecularly dispersing drospirenone in a carrier or spraying drospirenone onto carrier particles.
  • drospirenone in a carrier after co-milling is present in amorphous form (see X- ray diffraction patterns, Figures 6, 11 , 15 and 25). This is in agreement with the X-ray diffraction patterns of the drospirenone in the solid solution and the drospirenone being sprayed onto a carrier described in the prior art. In contrary, after micronization drospirenone is still present in crystalline form, rendering the dissolution behavior dependent on the selected particle size.
  • drospirenone is not distributed homogeneously throughout a dissolution controlling matrix but new fast dissolving drospirenone / carrier particles are formed having areas rich and poor in drospirenone.
  • the new co-milled particles combine the advantages of a fast release of drospirenone but avoid the disadvantages of other formulations known in the art for steroidal drugs.
  • the co-milling procedure avoids the need of solvents thus reducing the risk of decomposition of drospirenone and avoiding the problems associated with residual solvent molecules in pharmaceutical compositions.
  • the co- milling procedure does not require technically sophisticated and expensive equipment as it is needed for the micronization procedure.
  • the co-milling has an economic advantage over the micronization process, too.
  • the pharmaceutical composition according to the present invention comprising drospirenone and a pharmaceutically acceptable carrier in a co-milled state combines the advantages of the fast release of drospirenone and the good chemical and morphological stability of drospirenone, in particular by avoiding destabilization of drospirenone due to the absence of any solvent. Furthermore, the pharmaceutical composition provides excellent flow properties and can thus easily be further processed into solid pharmaceutical compositions, such as tablets. These advantageous characteristics of the pharmaceutical composition are also fully retained when the composition is processed into solid dosage form, e.g. a tablet. In particular, direct compression, which is preferred according to the present invention, does not entail any negative change in morphology, dissolution and stability of drospirenone by the formulation process.
  • the present invention also relates to the use of a pharmaceutically acceptable carrier selected from the group consisting of hydroxypropylmethylcellulose (HPMC), polyvinylpyrrolidone (PVP), and microcrystalline cellulose (MCC) for the preparation of a pharmaceutical composition comprising drospirenone substantially in amorphous form and wherein the pharmaceutically acceptable carrier and drospirenone are present in a co- milled state.
  • a pharmaceutically acceptable carrier selected from the group consisting of hydroxypropylmethylcellulose (HPMC), polyvinylpyrrolidone (PVP), and microcrystalline cellulose (MCC)
  • Figure 1 shows the powder X-ray diffraction pattern of crystalline drospirenone.
  • Figure 2 shows the DSC of crystalline drospirenone.
  • Figure 3 shows the Raman spectrum of drospirenone.
  • Figure 4 shows the Raman spectrum of HPMC.
  • Figure 5 shows the overlaid Raman spectra of drospirenone (API) and HPMC.
  • Figure 6 shows the powder X-ray diffraction pattern of drospirenone/HPMC co-milled particles according to the present invention, Example 1.
  • Figure 7 shows the DSC of drospirenone/HPMC co-milled particles according to the present invention, Example 1.
  • Figure 8 shows the Raman image of drospirenone/HPMC co-milled particles according to the present invention, Example 1.
  • Figure 9 shows the Raman spectrum of drospirenone/HPMC co-milled particles at the "cross" area in Figure 8.
  • Figure 10 shows the Raman spectrum of drospirenone/HPMC co-milled particles at the "circle” area in Figure 8.
  • Figure 11 shows the powder X-ray diffraction pattern of drospirenone/PVP co-milled particles according to the present invention, Example 3.
  • Figure 12 shows the DSC of drospirenone/PVP co-milled particles according to the present invention, Example 3.
  • Figure 13 shows the dissolution profiles of crystalline drospirenone (API) and several drospirenone co-milled formulations in 0.1 N HCL.
  • Figure 14 shows the dissolution profiles of crystalline drospirenone (API) and several drospirenone co-milled formulations in water.
  • Figure 15 shows the powder X-ray diffraction pattern of drospirenone/HPMC co-milled particles according to the present invention, Example 1, after open storage for 14 days at 40 0 C, 75 % rh (relative humidity).
  • Figure 16 shows the Raman image of micronized drospirenone blended in HPMC according to the prior art (WO 2001/015701).
  • Figure 17 shows the Raman spectrum of micronized drospirenone blended in HPMC at the "cross" area in Figure 16.
  • Figure 18 shows the Raman spectrum of micronized drospirenone blended in HPMC at the "circle" area in Figure 16.
  • Figure 19 shows the Raman image of molecularly dispersed drospirenone in HPMC (solid solution) according to the prior art (WO 2005/087194).
  • Figure 20 shows the Raman spectrum of molecularly dispersed drospirenone in HPMC (solid solution) at the "cross" area in Figure 19.
  • Figure 21 shows the Raman spectrum of molecularly dispersed drospirenone in HPMC (solid solution) at the "circle” area in Figure 19.
  • Figure 22 shows the Raman image of drospirenone sprayed onto HPMC according to the prior art (WO 2005/087199).
  • Figure 23 shows the Raman spectrum of drospirenone sprayed onto HPMC at the "cross" area in Figure 22.
  • Figure 24 shows the Raman spectrum of drospirenone sprayed onto HPMC at the "circle” area in Figure 22.
  • Figure 25 shows the powder X-ray diffraction patterns of a prior art preparation obtained by spraying drospirenone (DRSP) onto HPMC granules, a prior art preparation being a solid solution of DRSP in HPMC 1 a prior art formulation being a blend of micronized DRSP and HPMC and a co-milled formulation of DRSP and HPMC according to the invention (from upper to lower diagram).
  • DRSP drospirenone
  • a calibration curve was generated for drospirenone in the range of 22-54 ⁇ /mL which was found to be linear with an r 2 value of 0.9987.
  • the sample (150 mg) was spread onto the sample holder. The sample was then loaded into a Philips X-Pert MPD diffractometer, and the sample was analysed using the following experimental conditions.
  • Sample quantity Formulations were added so that each dissolution vessel equivalent of 3 mg of API.
  • the formulations and API were filled into size "1" hard gelatine capsules which were then placed into the dissolution vessels.
  • Raman mapping was carried out using a Nicolet Almega XR Dispersive Raman Microscope. Raman mapping parameters were as follows:
  • the Raman images represent the intensities of the signals at the chosen wavelengths (i.e. ⁇ 1590 cm “1 for the API, and ⁇ 1450 cm “1 for the carrier).
  • the absolute intensities of both signals correlate with each other and actually correlate with the physical topography of the sample. This is effectively the "background noise" from preparing the samples, i.e. the absolute intensity of the signals due to both the API and excipient correlate with the shape of the sample.
  • the ratio of the intensity of the signal due to the API to the intensity of the signal due to the excipient is determined.
  • the intensity of the Raman signal is different between the API and the excipient.
  • the API gives a strong Raman signal typically in the region of 1000 cm “1 to 1500 cm “1 .
  • the excipient gives a weak Raman signal, typically in the region of 50 cm “1 to 100 cm “1 .
  • the Raman probe provides a resolution of roughly 0.5 x 0.5 microns.
  • regions of mostly API that are larger than 0.5 x 0.5 ⁇ m give a strong response in the Raman mapping
  • regions in the mapping that give weak Raman response indicate less API content.
  • drospirenone 1 g of drospirenone and 2 g of HPMC were blended in a planetary ball mill (Pulverisette ® ) for a period of 12 - 48 hours.
  • the resulting co-milled composition was divided into single dosages containing 3 mg of drospirenone each.
  • Co-milled particles from drospirenone were prepared by blending 1 g of drospirenone, 1.3 g of Povidone and 2 g of HPMC in an agitator ball mill for a period of 0.5 - 3 hours. The resulting co-milled composition was divided into single dosages containing 3 mg of drospirenone each.
  • the formulation was prepared according to Example 1 or 2 using 1 g of drospirenone and
  • the formulation was prepared according to Example 1 or 2 using 1 g of drospirenone and 3 g of Povidone K30.
  • the formulation was prepared according to Example 1 or 2 using 1 g of drospirenone and 3 g of microcrystalline cellulose.
  • Co-milled particles of drospirenone were prepared according to Example 1 or 2 (I).
  • 1 g of lactose monohydrate was sieved, 10 mg of ethinylestradiol were added and both ingredients were premixed in a plastic bag (II).
  • 12.7 g of lactose, 8 g of maize starch (and 1.3 g of povidone if co-milled particles are prepared according to Example 1) were sieved, added to the processor and bjended for 5 min.
  • (I) and (II) were added to this excipient mixture and blended for another 15 - 20 min.
  • the dry mixture was sieved, 0.3 g of magnesium stearate were added and the final mixture was blended for another 3 - 5 min.
  • the mixture was further processed to tablets of the above composition by direct compression.
  • the obtained tablets may be coated using suitable pharmaceutically acceptable coating agents.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant du drospirénone, une composition pharmaceutique solide s'obtenant par compression de ladite composition pharmaceutique, et un procédé d'élaboration de ladite composition pharmaceutique.
PCT/EP2009/003409 2008-05-14 2009-05-13 Composition pharmaceutique comprenant du drospirénone WO2009138224A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08008918 2008-05-14
EP08008918.8 2008-05-14

Publications (1)

Publication Number Publication Date
WO2009138224A1 true WO2009138224A1 (fr) 2009-11-19

Family

ID=39735364

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/003409 WO2009138224A1 (fr) 2008-05-14 2009-05-13 Composition pharmaceutique comprenant du drospirénone

Country Status (1)

Country Link
WO (1) WO2009138224A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011128336A1 (fr) 2010-04-15 2011-10-20 Bayer Pharma Aktiengesellschaft Formes pharmaceutiques orales solides à très faible dose pour hrt
WO2011128337A2 (fr) 2010-04-15 2011-10-20 Bayer Pharma Aktiengesellschaft Forme galénique orale solide à faible dose pour le ths
WO2012000981A1 (fr) 2010-06-29 2012-01-05 Laboratorios Leon Farma Sa Composition pharmaceutique contenant de la drospirénone et kit contraceptif
US20150290222A1 (en) * 2010-07-28 2015-10-15 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
KR20190073598A (ko) * 2010-06-29 2019-06-26 라보라토리오스 레온 파르마 에스에이 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
WO2023152658A1 (fr) 2022-02-10 2023-08-17 Lupin Limited Composition de comprimé de drospirénone à libération lente

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001015701A1 (fr) * 1999-08-31 2001-03-08 Schering Aktiengesellschaft Melange pharmaceutique d'ethinylestradiol et de drospirenone utilise en tant que contraceptif
WO2005087199A2 (fr) * 2004-03-10 2005-09-22 Schering Aktiengesellschaft Matieres solides sursaturees stabilisees de medicaments lipophiles
WO2005087194A1 (fr) * 2004-03-10 2005-09-22 Schering Aktiengesellschaft Compositions comprenant de la drospirenone moleculairement dispersee

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001015701A1 (fr) * 1999-08-31 2001-03-08 Schering Aktiengesellschaft Melange pharmaceutique d'ethinylestradiol et de drospirenone utilise en tant que contraceptif
WO2005087199A2 (fr) * 2004-03-10 2005-09-22 Schering Aktiengesellschaft Matieres solides sursaturees stabilisees de medicaments lipophiles
WO2005087194A1 (fr) * 2004-03-10 2005-09-22 Schering Aktiengesellschaft Compositions comprenant de la drospirenone moleculairement dispersee

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUPTA MANISH K ET AL: "Formation of physically stable amorphous drugs by milling with Neusilin.", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 92, no. 3, March 2003 (2003-03-01), pages 536 - 551, XP002496655, ISSN: 0022-3549 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592245B2 (en) 2010-04-15 2017-03-14 Bayer Intellectual Property Gmbh Very low-dosed solid oral dosage forms for HRT
WO2011128337A2 (fr) 2010-04-15 2011-10-20 Bayer Pharma Aktiengesellschaft Forme galénique orale solide à faible dose pour le ths
WO2011128336A1 (fr) 2010-04-15 2011-10-20 Bayer Pharma Aktiengesellschaft Formes pharmaceutiques orales solides à très faible dose pour hrt
EP4056186A1 (fr) 2010-06-29 2022-09-14 Laboratorios Leon Farma SA Composition pharmaceutique comprenant de la drospirénone et ensemble contraceptif
US11452695B2 (en) 2010-06-29 2022-09-27 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US11951213B2 (en) 2010-06-29 2024-04-09 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
KR102539030B1 (ko) * 2010-06-29 2023-05-31 라보라토리오스 레온 파르마 에스에이 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
EP3632448B1 (fr) 2010-06-29 2022-01-12 Laboratorios Leon Farma SA Composition pharmaceutique comprenant de la drospirénone pour utilisation comme contraceptif
KR20170085604A (ko) * 2010-06-29 2017-07-24 라보라토리오스 레온 파르마 에스에이 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
EA028680B1 (ru) * 2010-06-29 2017-12-29 Лабораториос Леон Фарма Са Фармацевтическая композиция, содержащая дроспиренон, и набор для предупреждения зачатия
KR20190073598A (ko) * 2010-06-29 2019-06-26 라보라토리오스 레온 파르마 에스에이 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
EP3632448A1 (fr) 2010-06-29 2020-04-08 Laboratorios Leon Farma SA Composition pharmaceutique comprenant de la drospirénone et ensemble contraceptif
KR102164693B1 (ko) * 2010-06-29 2020-10-13 라보라토리오스 레온 파르마 에스에이 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
US11504334B2 (en) 2010-06-29 2022-11-22 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US11491113B1 (en) 2010-06-29 2022-11-08 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
KR20210013663A (ko) * 2010-06-29 2021-02-04 라보라토리오스 레온 파르마 에스에이 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
US11478487B1 (en) 2010-06-29 2022-10-25 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AU2011273605A8 (en) * 2010-06-29 2016-07-28 Laboratorios Leon Farma, S.A. Pharmaceutical composition comprising drospirenone and contraceptive kit
AU2011273605B2 (en) * 2010-06-29 2016-05-26 Laboratorios Leon Farma, S.A. Pharmaceutical composition comprising drospirenone and contraceptive kit
KR102210982B1 (ko) * 2010-06-29 2021-02-02 라보라토리오스 레온 파르마 에스에이 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
WO2012000981A1 (fr) 2010-06-29 2012-01-05 Laboratorios Leon Farma Sa Composition pharmaceutique contenant de la drospirénone et kit contraceptif
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US11413249B2 (en) 2010-07-28 2022-08-16 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US11439598B2 (en) 2010-07-28 2022-09-13 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US11291632B2 (en) 2010-07-28 2022-04-05 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9603860B2 (en) * 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US10987364B1 (en) 2010-07-28 2021-04-27 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US11291633B2 (en) 2010-07-28 2022-04-05 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US20150290222A1 (en) * 2010-07-28 2015-10-15 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11123299B2 (en) 2010-07-28 2021-09-21 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
WO2023152658A1 (fr) 2022-02-10 2023-08-17 Lupin Limited Composition de comprimé de drospirénone à libération lente

Similar Documents

Publication Publication Date Title
WO2009138224A1 (fr) Composition pharmaceutique comprenant du drospirénone
EP2579859B1 (fr) Composition solide contenant de l'ivabradine
US20140248347A1 (en) Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
CA2747311A1 (fr) Composition solide comportant l'agent actif rasagiline
WO2017195144A1 (fr) Compositions pharmaceutiques comprenant du brivaracétam
WO2015129893A1 (fr) Composition pharmaceutique pour administration orale
TW202227067A (zh) Ｍａｌｔ１抑制劑之無定形形式及其配製物
US20210401860A1 (en) Pharmaceutical formulations comprising 5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine
US20230183205A1 (en) Pharmaceutical composition in which production of impurities is suppressed
Desai et al. Solid-state interaction of stearic acid with povidone and its effect on dissolution stability of capsules
EP3876991A1 (fr) Nouveaux principes actifs pharmaceutiques amorphes comprenant du carbonate de magnésium mésoporeux sensiblement amorphe
EP3545949A1 (fr) Formes posologiques orales comprenant une forme cristalline a de pomalidomide
JP7264711B2 (ja) レベチラセタム含有医薬組成物の製造方法
US11123300B2 (en) Immediate release tablet of a benzothiophene compound
EP3572069A1 (fr) Augmentation de la solubilité et de la biodisponibilité de l'enzalutamide
US20210087175A1 (en) Crystalline Form II of Darolutamide
EP3079672B1 (fr) Composition pharmaceutique comprenant un sel pharmaceutiquement acceptable de rasagiline
WO2022176877A1 (fr) Matériau amorphe, et composition contenant celui-ci
US20110263701A1 (en) Gabapentin enacarbil compositions
EP3811932A1 (fr) Forme posologique d'apalutamide
KR20110115607A (ko) 6-옥소-6,7,8,9,10,11-헥사히드로시클로헵타(ｃ)크로멘-3-일 술파메이트 및 그의 다형체를 함유하는 고체 제약 조성물
CN117257752A (zh) 药物组合物及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09745558

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09745558

Country of ref document: EP

Kind code of ref document: A1